Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease

Genevieve M. Leyden, View ORCID ProfileTom R. Gaunt, View ORCID ProfileTom G. Richardson
doi: https://doi.org/10.1101/2020.02.16.20023010
Genevieve M. Leyden
1MRC Integrative Epidemiology Unit, University of Bristol
2Bristol Medical School: Translational Health Sciences, University of Bristol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tom R. Gaunt
1MRC Integrative Epidemiology Unit, University of Bristol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tom R. Gaunt
Tom G. Richardson
1MRC Integrative Epidemiology Unit, University of Bristol
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Tom G. Richardson
  • For correspondence: Tom.G.Richardson@bristol.ac.uk
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

Abstract

Importance New drugs which provide benefit alongside statin mono-therapy are warranted to reduce risk of cardiovascular disease.

Objective To systematically evaluate the genetically predicted effects of 8,851 genes and cardiovascular disease risk factors using data from the UK Biobank and subsequently prioritize their potential to reduce cardiovascular disease in addition to statin therapy.

Design, Setting, and Participants A factorial Mendelian randomization study using individual level data from the UK Biobank study. This population-based cohort includes a total of 502,602 individuals aged between 40 and 96 years old at baseline who were recruited between 2006 to 2010.

Exposures Genetic variants robustly associated with the expression of target genes in whole blood (based on P<5×10−08) were used to construct gene scores using findings from the eQTLGen consortium (n=31,684).

Main Outcomes and Measures Genetically predicted effects for each of the 8,851 genes were firstly evaluated with 5 measured outcomes from the UK Biobank in turn (body mass index, diastolic blood pressure, systolic blood pressure, low-density lipoproteins and triglycerides). Effects surviving multiple comparisons from this initial analysis were subsequently analyzed using factorial Mendelian randomization to evaluate evidence of an additive beneficial effect on cardiovascular disease risk compared to a HMGCR genetic score acting as a proxy for statin inhibition. Finally, a phenome-wide analysis was undertaken to evaluate predicted effects between prioritized targets and 569 outcomes in the UK Biobank to highlight potential adverse side-effects.

Results 377 genetically predicted effects on cardiovascular disease risk factors were identified by Mendelian randomization (based on P<1.13×10−6). Of the 68 druggable genes, 20 candidate genes were predicted to lower cardiovascular disease risk in combination with statin treatment (P<7.35×10−4). Genes such as FDFT1 were predicted to have added benefit with statin therapy (OR=0.93; 95% CI, 0.91-0.95; P=2.21×10−10) but are unlikely to make safe targets due to their predicted effects on adverse side effects. In contrast, PRKCE provided evidence of a putative added benefit in combination with statins (OR=0.94; CI, 0.91-0.96; P=1.72×10−9) with no predicted adverse effects.

Conclusions and Relevance Through the application of a systematic factorial Mendelian randomization analysis, we have prioritized (and deprioritized) potential drug targets predicted to reduce cardiovascular disease risk in addition to statin therapy.

Question Can naturally occurring genetic variation in a population help us highlight and prioritize novel therapeutic targets for the treatment of cardiovascular disease?

Findings In this factorial Mendelian randomization study of 334,915 individuals, we found that a genetically predicted 0.09 mmol/L decrease in LDL cholesterol attributed to statin inhibition results in 4.1% lower risk of cardiovascular disease. We then highlighted various genetic targets which were genetically predicted to further reduce disease risk without evidence of adverse side effects, such as PRKCE which is involved in the development of cardiac hypertrophy and reduced risk of cardiovascular disease by 6.4% in addition to statin therapy.

Meaning Evidence from genetic analyses can improve the likelihood of success for therapeutic targets and findings from this study have prioritized several promising candidates for the treatment of cardiovascular disease.

Competing Interest Statement

TRG receives research funding from GlaxoSmithKline and Biogen although neither company contributed to design or implementation of this study.

Funding Statement

This work was supported by the Integrative Epidemiology Unit which receives funding from the UK Medical Research Council and the University of Bristol (MC_UU_00011/4). GML is supported by the British Heart Foundation (FS/17/60/33474). TGR is a UKRI Innovation Research Fellow (MR/S003886/1).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

Summary statistics used in this study are available from the eQTLGen consortium (https://www.eqtlgen.org/) and the MR-Base platform (http://www.mrbase.org/). All individual-level data analysed in this study can be accessed with an application to the UK Biobank study (https://www.ukbiobank.ac.uk/).

  • Abbreviations

    CVD
    Cardiovascular disease
    RCT
    Randomized control trial
    MR
    Mendelian Randomization
    GWAS
    Genome wide association study
    eQTL
    expression quantitative loci
    UKB
    UK Biobank
    PheWAS
    Phenome wide association study
    SNP
    Single nucleotide polymorphism
    BMI
    Body mass index
    DBP
    Diastolic blood pressure
    SBP
    Systolic blood pressure
    LDL
    Low-density lipoproteins
    TG
    Triglycerides
    IVW
    Inverse variance weighted
    GRS
    Genetic risk score
  • Copyright 
    The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
    Back to top
    PreviousNext
    Posted February 20, 2020.
    Download PDF
    Data/Code
    Email

    Thank you for your interest in spreading the word about medRxiv.

    NOTE: Your email address is requested solely to identify you as the sender of this article.

    Enter multiple addresses on separate lines or separate them with commas.
    A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease
    (Your Name) has forwarded a page to you from medRxiv
    (Your Name) thought you would like to see this page from the medRxiv website.
    CAPTCHA
    This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
    Share
    A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease
    Genevieve M. Leyden, Tom R. Gaunt, Tom G. Richardson
    medRxiv 2020.02.16.20023010; doi: https://doi.org/10.1101/2020.02.16.20023010
    Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
    Citation Tools
    A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease
    Genevieve M. Leyden, Tom R. Gaunt, Tom G. Richardson
    medRxiv 2020.02.16.20023010; doi: https://doi.org/10.1101/2020.02.16.20023010

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
    • Tweet Widget
    • Facebook Like
    • Google Plus One

    Subject Area

    • Genetic and Genomic Medicine
    Subject Areas
    All Articles
    • Addiction Medicine (216)
    • Allergy and Immunology (496)
    • Anesthesia (106)
    • Cardiovascular Medicine (1110)
    • Dentistry and Oral Medicine (196)
    • Dermatology (141)
    • Emergency Medicine (275)
    • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
    • Epidemiology (9796)
    • Forensic Medicine (5)
    • Gastroenterology (481)
    • Genetic and Genomic Medicine (2327)
    • Geriatric Medicine (223)
    • Health Economics (463)
    • Health Informatics (1567)
    • Health Policy (737)
    • Health Systems and Quality Improvement (608)
    • Hematology (238)
    • HIV/AIDS (508)
    • Infectious Diseases (except HIV/AIDS) (11669)
    • Intensive Care and Critical Care Medicine (617)
    • Medical Education (240)
    • Medical Ethics (67)
    • Nephrology (258)
    • Neurology (2154)
    • Nursing (134)
    • Nutrition (340)
    • Obstetrics and Gynecology (427)
    • Occupational and Environmental Health (519)
    • Oncology (1185)
    • Ophthalmology (366)
    • Orthopedics (129)
    • Otolaryngology (221)
    • Pain Medicine (148)
    • Palliative Medicine (50)
    • Pathology (314)
    • Pediatrics (699)
    • Pharmacology and Therapeutics (303)
    • Primary Care Research (268)
    • Psychiatry and Clinical Psychology (2195)
    • Public and Global Health (4685)
    • Radiology and Imaging (786)
    • Rehabilitation Medicine and Physical Therapy (458)
    • Respiratory Medicine (625)
    • Rheumatology (276)
    • Sexual and Reproductive Health (226)
    • Sports Medicine (212)
    • Surgery (252)
    • Toxicology (43)
    • Transplantation (120)
    • Urology (94)